LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Listă Acțiuni・Novartis AG

Novartis AG

Deschisă

116.77 1.06

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

115.54

Maxim

116.79

Indicatori cheie
By Trading Economics
Venit	2.7B
Vânzări	344M 12B
P/E Medie Sector	23.59 103.001
EPS	1.31
Marjă de profit	22.178
EBITDA	4.7B

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+2.96 upside

Statistici piață
By TradingEconomics
Capitalizare de piață	818M 247B
Deschiderea anterioară	115.71
Închiderea anterioară	116.77

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

115.28 / 117.16 Suport & Rezistență

Novartis AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 aug. 2024, 09:47 UTC

Achiziții, Fuziuni, Preluări

Novartis Confirms Offer for Diagnostic Arm From Siemens Healthineers

18 iul. 2024, 05:58 UTC

Câștiguri

Novartis Raises Profit Guidance as Key Drugs Boost Sales -- Update

18 iul. 2024, 05:42 UTC

Câștiguri

Novartis Raises Profit Guidance as Key Drugs Boost Sales

9 sept. 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3 sept. 2024, 14:07 UTC

Market Talk

Novartis Has a Strong Drug Pipeline But Investor Optimism Is Yet to Grow -- Market Talk

19 aug. 2024, 13:36 UTC

Market Talk

Novartis Well on Track to Achieve Guidance -- Market Talk

14 aug. 2024, 09:02 UTC

Market Talk

Novartis Could Slash Guidance Amid Generic Heart-Drug Competition -- Market Talk

18 iul. 2024, 11:55 UTC

Câștiguri

Novartis Reports Near 40% Margin In Q2; Shares Slide -- IBD

18 iul. 2024, 09:40 UTC

Market Talk

Câștiguri

Novartis 2Q Results Seem Solid, Catalysts in Focus -- Market Talk

18 iul. 2024, 08:45 UTC

Market Talk

Câștiguri

Novartis Sales Beat Reflects Demand for New Drugs, Older Blockbusters Lag -- Market Talk

18 iul. 2024, 07:48 UTC

Market Talk

Novartis Prostate-Cancer Drug Pluvicto Sales Miss Raises Growth Questions -- Market Talk

18 iul. 2024, 07:01 UTC

Market Talk

Câștiguri

Novartis Profit Outlook Lift Reflects Blockbuster Drug Sales Boost, Operational Execution -- Market Talk

18 iul. 2024, 05:18 UTC

Câștiguri

Correct: Novartis 2Q Core Operating Profit $4.95B

18 iul. 2024, 05:03 UTC

Câștiguri

Novartis Had Seen Net Sales to Grow High-Single to Low Double-digit in 2024

18 iul. 2024, 05:03 UTC

Câștiguri

Novartis Net Sales Guidance in 2024 Unchanged

18 iul. 2024, 05:03 UTC

Câștiguri

Novartis Had Seen Core Operating Income to Grow Low Double-Digit to Mid-Teens in 2024

18 iul. 2024, 05:03 UTC

Câștiguri

Novartis Expects Core Operating Income to Grow Mid- to High Teens in 2024

18 iul. 2024, 05:02 UTC

Câștiguri

Novartis Raises 2024 Guidance

18 iul. 2024, 05:01 UTC

Câștiguri

Analysts Had 2Q Core Operating Profit at $4.67B

18 iul. 2024, 05:01 UTC

Câștiguri

Analysts Had 2Q Sales at $12.22B

18 iul. 2024, 05:01 UTC

Câștiguri

Novartis 2Q Sales $12.51B

18 iul. 2024, 05:01 UTC

Câștiguri

Novartis 2Q Core Operating Profit $12.51B

18 iul. 2024, 05:00 UTC

Câștiguri

Novartis AG 2Q EPS $1.60

18 iul. 2024, 05:00 UTC

Câștiguri

Novartis AG 2Q Adj EPS $1.97

18 iul. 2024, 05:00 UTC

Câștiguri

Novartis AG 2Q Net Pft $3.2B

20 iun. 2024, 06:35 UTC

Achiziții, Fuziuni, Preluări

MorphoSys Delisting From Frankfurt Stock Exchange, Nasdaq Expected to Take Place in 3Q

20 iun. 2024, 06:34 UTC

Achiziții, Fuziuni, Preluări

Novartis Delisting Offer Is In Line With Price of Acquisition Closed in May

20 iun. 2024, 06:33 UTC

Achiziții, Fuziuni, Preluări

Novartis to Offer EUR68 a Share in Cash to Minority MorphoSys Shareholders

20 iun. 2024, 06:32 UTC

Achiziții, Fuziuni, Preluări

Novartis Holds Around 91.04% of MorphoSys as of Thursday

20 iun. 2024, 06:31 UTC

Achiziții, Fuziuni, Preluări

Novartis to Start Squeeze-Out of MorphoSys' Minority Shareholders

Comparație

Modificare preț

Novartis AG Așteptări

Obiectiv de preț

By TipRanks

2.96% sus

Prognoză pe 12 luni

Medie 119.08 USD 2.96%

Maxim 130 USD

Minim 97 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovartis AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Novartis AG - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

115.28 / 117.16Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.